title: [Efficacy of trastuzumab alone therapy was compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancers].
abstract: We compared trastuzumab alone therapy (A-group) (n=6) to trastuzumab plus taxane therapy (B-group) (n=12) in patients of advanced and metastatic breast cancers. The response rate of A-group was 33.3%. Six months after, A-group was switched to trastuzumab plus taxane therapy. The response rate of A-group after addition of taxane was improved to 83.3%. The mean duration of response was 6.8 months in A-group after addition of taxane. The response rate of B-group was 83.3%. The mean duration of response was 7.5 months in B-group. The combination therapy of trastuzumab and taxane therapy showed a high response rate. We think that it is possible to start trastuzumab alone therapy because A-group after addition of taxane showed a high response rate. There were no significant differences of immunosuppressive acidic protein (IAP) from the course of chemotherapy in all cases.
authors.affiliation: Division of Breast and Endocrine Surgery, Dept. of Surgery, Nihon University School of Medicine.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sakurai
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Enomoto
authors.forename: Akira
authors.initials: A
authors.lastname: Kitajima
authors.forename: Mayumi
authors.initials: M
authors.lastname: Tani
authors.forename: Sadao
authors.initials: S
authors.lastname: Amano
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D001952:Bridged-Ring Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane; D000068878:Trastuzumab